Alcon Receives Regulatory Approval for OTC Brytly Eye Drops

Key Facts

1Alcon has received approval for its Brytly eye drops to be sold as an over-the-counter (OTC) product.

Alcon has received regulatory approval to market its Brytly eye drops as an over-the-counter (OTC) product. Seeking Alpha reported that the approval enables the company to expand its consumer healthcare portfolio by offering Brytly directly to consumers without a prescription.

ALC closed at $66.58 on October 15, 2026, with the stock reaching a day high of $66.79 and a low of $65.02. This regulatory milestone is expected to enhance the company's market reach and revenue potential within the ophthalmology sector.